7,8-Dimethoxycoumarin

7,8-Dimethoxycoumarin is a coumarin compound derived from Artemisia caruifolia with oral activity. 7,8-Dimethoxycoumarin inhibits mitochondrial permeability transition pore and H⁺/K⁺-ATPase, and exhibits antioxidant, anti-inflammatory, renoprotective, neuroprotective and gastroprotective effects. 7,8-Dimethoxycoumarin reduces lipid peroxidation (TBARS), increases GSH levels, inhibits myeloperoxidase (MPO) activity, and regulates the expression of inflammatory factors by inhibiting the NF‑κB and MAPK pathways. 7,8-Dimethoxycoumarin ameliorates gastric mucosal injury, alleviates renal tissue lesions and relieves neuropathic pain. 7,8-Dimethoxycoumarin can be used in studies related to acute renal failure, trigeminal neuralgia and gastritis^[1][2][3][4]. In Vitro: 7,8-Dimethoxycoumarin (DMC) protects human keratinocyte HaCaT cells from TNF-α-induced damage through inhibition of NF-κB activation and MAPK phosphorylation^[2].
7,8-Dimethoxycoumarin stimulates melanogenesis via MAPK-mediated MITF upregulation and reduces IL-6, IL-8, and CCL2/MCP-1 expression in TNF-α-treated HaCaT cells^[3]. In Vivo: 7,8-Dimethoxycoumarin (50-100 mg/kg; p.o.; daily; 6 consecutive days) ameliorates Cisplatin (HY-17394)-induced acute renal failure in male Sprague Dawley rats in a dose-dependent manner, with the 75 and 100 mg/kg doses producing significant renoprotective effects comparable to Cyclosporin A (HY-B0579)^[1].
7,8-Dimethoxycoumarin (100-200 mg/kg; p.o.; daily; 10 consecutive days) dose-dependently attenuates TNF-α-induced trigeminal neuralgia in rats and reversing oxidative stress and histopathological damage^[2].
7,8-Dimethoxycoumarin (50-100 mg/kg; i.p.; single dose 1 hour pre-ligation) exerts significant gastroprotective and anti-inflammatory effects in pyloric ligation-induced gastritis in rats at a dose of 100 mg/kg^[4].